Form 4: Nuvalent's Chief Scientific Officer, Henry E. Pelish, Executes Stock Sales Under 10b5-1 Plan

Henry E. Pelish, Chief Scientific Officer of Nuvalent, Inc., sold shares of Class A Common Stock on September 16, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On September 16, 2024, Henry E. Pelish, the Chief Scientific Officer of Nuvalent, Inc., sold multiple blocks of Class A Common Stock.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 15, 2023.
• The transactions involved the sale of varying amounts of stock at different weighted average prices, ranging from $93.25 to $102.8 per share.
• Following these transactions, Pelish directly owns 33,300 shares of Class A Common Stock.
• The reporting person has committed to providing full information regarding the number of shares sold at each separate price within the specified ranges upon request.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock sales by an executive, which is neither inherently positive nor negative. The use of a 10b5-1 plan suggests pre-planned and orderly transactions.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions and provides transparency to the market regarding the trading activities of company executives. It is common for executives to utilize 10b5-1 trading plans to sell shares over time to avoid accusations of trading on inside information.

Stakeholder Impact

• The stock sales could have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.
• The transactions do not directly impact employees, customers, suppliers, or creditors.

Key Dates